COVID-19: The COVID-19 infection situation was used as an intervention measure, and the cohort was divided into groups.
Study summary
This study was designed as a single-center retrospective analysis aimed at investigating whether COVID-19 infection increases the risk or burden of radiation-induced pneumonitis in breast cancer patients.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
1. patients with pathologically or cytologically confirmed primary breast cancer,
2. aged 18 years or older but younger than 80 years,
3. with complete and reliable medical records,
4. for those with COVID-19 infection, documented evidence of a positive test result.
Exclusion Criteria:
1. concomitant pulmonary malignancies,
2. a history of prior thoracic radiotherapy,
3. concurrent pulmonary infections other than COVID-19 during radiotherapy,
4. missing key data with loss to follow-up,
5. or any other condition considered unsuitable for enrollment by the investigators.
Primary outcome measure(s)
Radiation Pneumonitis Situation — From January 2021 to June 2024 The incidence rate, severity and onset time of radiation pneumonitis
Trial sites (1)
Facility
City
Region
Status
Zhejiang Hospital, Department of Oncology, Hangzhou, China, 310030
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.